Japan accepts GSK Arexvy regulatory application to prevent RSV disease in adults aged 50-59 at increased risk
London: GSK plc has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a regulatory application to extend the indication of GSK’s respiratory syncytial virus (RSV) vaccine (recombinant adjuvanted) for the prevention of RSV disease in adults aged 50-59 at increased risk. This regulatory submission follows Japan’s approval of GSK’s […]